The ‘miracle drug’ some dog owners regret using
Librela, a new drug to treat arthritis pain in dogs, was approved for use in Canada in 2021. In some cases, it was described to owners as a “miracle drug”, with no side effects other than potential soreness and swelling at the injection site. Some owners describe their dogs seeming happier and more comfortable. But others have reported adverse reactions, including lethargy, disorientation, vomiting, and even death. Zoetis, Librela’s parent company, says Librela is safe and was rigorously tested. Susan Krashinsky Robertson is a business reporter for the Globe. She spoke to eight people whose pets’ health declined after taking Librela. She’s on the show to talk about the promise of Librela, and what she heard from pet owners and veterinarians about the drug. Questions? Comments? Ideas? Email us at [email protected]
Audio is streamed directly from the publisher (afp-119681-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Librela, a new drug to treat arthritis pain in dogs, was approved for use in Canada in 2021. In some cases, it was described to owners as a “miracle drug”, with no side effects other than potential soreness and swelling at the injection site. Some owners describe their dogs seeming happier and more comfortable. But others have reported adverse reactions, including lethargy, disorientation, vomiting, and even death. Zoetis, Librela’s parent company, says Librela is safe and was rigorously tested.
Susan Krashinsky Robertson is a business reporter for the Globe. She spoke to eight people whose pets’ health declined after taking Librela. She’s on the show to talk about the promise of Librela, and what she heard from pet owners and veterinarians about the drug.
Questions? Comments? Ideas? Email us at [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.